BTT-1023: Phase IIa started

Biotie said investigators began the open-label, U.K. Phase IIa BUTEO trial to evaluate 7 doses of 8 mg/kg IV BTT1023 every 2 weeks over 11 weeks in 41 patients. The dose may be increased to 12 or 16 m...